File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation

TitleHow I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation
Authors
Issue Date2009
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
Blood, 2009, v. 113 n. 14, p. 3147-3153 How to Cite?
AbstractHepatitis B virus (HBV) reactivation is a serious but preventable complication of immunosuppression. Full HBV serologic profile must be obtained from all patients receiving intensive immunosuppressive therapy. In general, preemptive anti-HBV therapy is more effective than giving treatment after development of reactivation. Prompt lamivu-dine therapy should be given to at-risk patients who are hepatitis B surface antigen (HBsAg)-positive. It is recommended that lamivudine be continued until at least 6 months after the cessation of immunosuppression. Some patients requiring a longer duration of lamivudine therapy are at risk of developing drug resistance. The newer anti HBV agents are effective in overcoming lamivudine resistance. Early use of these agents may be considered. HBV reactivation was observed in HBsAg-negative patients with occult HBV infection (HBV DNA-positive) who are on heavy immunosuppression. The optimal management of this group of patients is unclear. For patients receiving allogeneic HSC transplants, the HBV status of the donors requires special attention. To minimize the risk of transmission of infection to recipients, HBsAg positive donors should receive adequate anti-HBV therapy before HSC donation. As the result of adoptive immune transfer, clearance of HBsAg is observed in HBsAg-positive patients receiving HSC transplants from donors who are positive for hepatitis B surface and core antibodies. © 2009 by The American Society of Hematology.
Persistent Identifierhttp://hdl.handle.net/10722/59226
ISSN
2015 Impact Factor: 11.841
2015 SCImago Journal Rankings: 6.395
ISI Accession Number ID
Funding AgencyGrant Number
S. H. Ho Charitable Foundation
Funding Information:

This work was supported by S. H. Ho Charitable Foundation.

References

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_HK
dc.date.accessioned2010-05-31T03:45:33Z-
dc.date.available2010-05-31T03:45:33Z-
dc.date.issued2009en_HK
dc.identifier.citationBlood, 2009, v. 113 n. 14, p. 3147-3153en_HK
dc.identifier.issn0006-4971en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59226-
dc.description.abstractHepatitis B virus (HBV) reactivation is a serious but preventable complication of immunosuppression. Full HBV serologic profile must be obtained from all patients receiving intensive immunosuppressive therapy. In general, preemptive anti-HBV therapy is more effective than giving treatment after development of reactivation. Prompt lamivu-dine therapy should be given to at-risk patients who are hepatitis B surface antigen (HBsAg)-positive. It is recommended that lamivudine be continued until at least 6 months after the cessation of immunosuppression. Some patients requiring a longer duration of lamivudine therapy are at risk of developing drug resistance. The newer anti HBV agents are effective in overcoming lamivudine resistance. Early use of these agents may be considered. HBV reactivation was observed in HBsAg-negative patients with occult HBV infection (HBV DNA-positive) who are on heavy immunosuppression. The optimal management of this group of patients is unclear. For patients receiving allogeneic HSC transplants, the HBV status of the donors requires special attention. To minimize the risk of transmission of infection to recipients, HBsAg positive donors should receive adequate anti-HBV therapy before HSC donation. As the result of adoptive immune transfer, clearance of HBsAg is observed in HBsAg-positive patients receiving HSC transplants from donors who are positive for hepatitis B surface and core antibodies. © 2009 by The American Society of Hematology.en_HK
dc.languageengen_HK
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/en_HK
dc.relation.ispartofBlooden_HK
dc.subject.meshAntibodies, Monoclonal - therapeutic useen_HK
dc.subject.meshHematopoietic Stem Cell Transplantation - methodsen_HK
dc.subject.meshHepatitis B - blood - diagnosis - immunology - therapyen_HK
dc.subject.meshHepatitis B Antibodies - blooden_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunosuppressive Agents - adverse effects - therapeutic useen_HK
dc.subject.meshImmunotherapy - methodsen_HK
dc.subject.meshMonitoring, Physiologic - methodsen_HK
dc.subject.meshTransplantation Conditioning - adverse effects - methodsen_HK
dc.subject.meshVirus Activation - drug effects - physiologyen_HK
dc.titleHow I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0006-4971&volume=113&issue=14&spage=3147&epage=3153.&date=2009&atitle=How+I+treat+and+monitor+viral+hepatitis+B+infection+in+patients+receiving+intensive+immunosuppressive+therapies+or+undergoing+hematopoietic+stem+cell+transplantationen_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1182/blood-2008-10-163493en_HK
dc.identifier.pmid19144986-
dc.identifier.scopuseid_2-s2.0-65349091448en_HK
dc.identifier.hkuros161857en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-65349091448&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume113en_HK
dc.identifier.issue14en_HK
dc.identifier.spage3147en_HK
dc.identifier.epage3153en_HK
dc.identifier.isiWOS:000264848900006-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.citeulike4531671-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats